ALK opjusterer forventningerne til omsætning og indtjening i 2024
21 juin 2024 12h43 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at forventningerne til helåret er blevet opjusteret som følge af bedre end forventet salgsudvikling i andet kvartal og forbedrede udsigter for...
ALK upgrades its full-year revenue and earnings outlook
21 juin 2024 12h43 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the full-year financial outlook has been upgraded to reflect better than expected sales performance in Q2 and an improved outlook for the...
ALK giver opdatering på registreringsprocessen for tabletten mod husstøvmideallergi i Kina
21 juin 2024 12h38 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag annonceret, at selskabet har besluttet at trække sin registreringsansøgning for tabletten mod husstøvmideallergi. ALK vil fortsat samarbejde med...
ALK provides update on regulatory process for the house dust mite allergy tablet in China
21 juin 2024 12h38 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that it has decided to withdraw the Biologic License Application (‘BLA’) for its house dust mite (‘HDM’) sublingual allergy immunotherapy tablet in...
ALK lancerer ny vækststrategi og finansielle ambitioner for 2028
03 juin 2024 12h02 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) har i dag meddelt, at bestyrelsen har vedtaget en ny selskabsstrategi (Allergy+) og finansielle ambitioner for 2028. Målet med Allergy+ er at udbygge ALK’s...
ALK launches new growth strategy and 2028 financial ambitions
03 juin 2024 12h02 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen...
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
03 juin 2024 01h00 HE
|
ALK Abello
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK...
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
30 mai 2024 07h44 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for...
Listen in on ALK’s Capital Markets Day on 4 June 2024
29 mai 2024 04h56 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will host a Capital Markets Day on 4 June at 13.00-17.00. We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital...
Three-month interim report (Q1) 2024 (unaudited)
02 mai 2024 13h43 HE
|
ALK Abello
Company release No. 11/2024 ALK delivers 10% organic revenue growth with operating profit up 41% in Q1 and upgrades outlookThe growth in ALK's overall sales was primarily driven by the European...